Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
Oren Gilad(Cancer Research Institute), Eric J. Brown(University of Pennsylvania), Barzin Y. Nabet(Gene Therapy Laboratory), David W. Schoppy(Cancer Research Institute), Amy C. Durham(Cancer Research Institute), Kevin D. Smith(Cancer Research Institute), Ryan L. Ragland(Cancer Research Institute)
Cited by 232
Related Papers
<i>ATR</i> disruption leads to chromosomal fragmentation and early embryonic lethality
|Genes & Development|2000|944
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930